Please login to the form below

Not currently logged in
Email:
Password:

Merck and Co

This page shows the latest Merck and Co news and features for those working in and with pharma, biotech and healthcare.

Incyte/Merck trial failure bodes ill for IDO class

Incyte/Merck trial failure bodes ill for IDO class

Ahead of the weekend, Incyte and partner Merck &Co were rocked by the news that their much-touted cancer immunotherapy combination had failed comprehensively in its first phase III test. ... The pairing of Incyte’s IDO1 inhibitor epacadostat and

Latest news

  • Sanofi’s PD-1 inhibitor starts EU review for skin cancer Sanofi’s PD-1 inhibitor starts EU review for skin cancer

    intended - to help it break into one of the most hotly-contested pharma markets, currently led by Bristol-Myers Squibb and Merck &Co/MSD. ... In addition to chasing companies in the category with already-marketed drugs - which also include Roche,

  • BMS gets OK for monthly Opdivo dosing BMS gets OK for monthly Opdivo dosing

    cancer. It is competing in the marketplace with two other PD-1 inhibitors - Merck &Co/MSD’s Keytruda (pembrolizumab) and Roche’s Tecentriq (atezolizumab) - as well as PD-L1 inhibitors Imfinzi ... durvalumab) from AstraZeneca and Merck KGaA/Pfizer’s

  • CHMP backs AZ’s Lynparza for ovarian cancer maintenance CHMP backs AZ’s Lynparza for ovarian cancer maintenance

    AstraZeneca and partner Merck &Co have moved a step closer to a second-line maintenance indication for PARP inhibitor Lynparza in ovarian cancer in the EU after a positive opinion from ... Lynparza can be used in these patients regardless of the

  • Pfizer’s leukaemia drug Mylotarg backed for use in EU Pfizer’s leukaemia drug Mylotarg backed for use in EU

    The CHMP also gave positive opinions to: a new maintenance indication for AstraZeneca and Merck &Co’s PARP inhibitor Lynparza (olaparib) in ovarian cancer; the use of Swedish orphan Biovitrum’s ... Kineret (anakinra) in rare inflammatory condition

  • Merck buys cancer-killing virus firm Viralytics for $394m Merck buys cancer-killing virus firm Viralytics for $394m

    Merck &Co has bolted on another immuno-oncology asset to pair with its flagship checkpoint inhibitor Keytruda in clinical trials. ... Analysts have suggested that another party is however unlikely to come forward at this stage, given the longstanding

More from news
Approximately 46 fully matching, plus 422 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    Beyond Pfizer, the biggest positive movers in the top 20 include Shire, Bayer and Merck &Co. ... 2020.”. Central Nervous System. 2017 was a quiet year in CNS. The most prominent growing companies were Merck &Co (49.8%), Takeda (39.1%) and Sumitomo

  • Deal Watch - May 2017 Deal Watch - May 2017

    More recent data reported in FiercePharma (1. st. May) shows Amgen has cash overseas of $34bn, Gilead $27bn and Merck &Co $22bn. ... It has signed deals with 10 companies in the last two years including Novartis, Genentech, Sanofi, Merck &Co and Lilly.

  • Deal Watch September 2016 Deal Watch September 2016

    Merck &Co has sold the US and Canadian rights for its Zontivity, or vorapaxar, to Aralez Pharmaceuticals in an asset purchase agreement worth $25m. ... 600. Verily / Sanofi. JV. Co-investment to form Onduo combining Sanofi's diabetes expertise with Verily

  • Deal Watch July 2016 Deal Watch July 2016

    It is a humanised inducible co-stimulator (ICOS) agonist antibody, designed to both stimulate T effector cells and selectively reduce intra-tumoural T regulatory cells. ... And Finally, Reality Bites. ALK-Abello has issued a press release announcing that

  • Deal Watch June 2016 Deal Watch June 2016

    Deal Watch June 2016. Allergan, Novartis and Merck &Co are among those featured in this month's round-up of pharma deal activity. ... The deal headline is around $150m and Merck &Co will pay tiered royalties on product sales.

More from intelligence
Approximately 0 fully matching, plus 34 partially matching documents found.

Latest appointments

  • Nabriva Therapeutics appoints chief medical officer Nabriva Therapeutics appoints chief medical officer

    Dr Schranz joins Nabriva from Irish biopharma Shire, with nearly two decades of experience in clinical development and medical affairs. ... Her career has seen her hold positions at Shire, ViroPharma, Pfizer, GlaxoSmithKline and Merck &Co.

  • Hansa Medical poaches Vifor Pharma’s CEO Hansa Medical poaches Vifor Pharma’s CEO

    Hansa Medical poaches Vifor Pharma’ s CEO. Søren Tulstrup becomes the Swedish biopharma’s CEO and president. ... Additionally, Tulstrup has served as CEO of Santaris Pharma, now part of Roche, and in several senior commercial roles within Merck &Co

  • Astellas promotes Anthony Fiordaliso to VP, Americas finance Astellas promotes Anthony Fiordaliso to VP, Americas finance

    He has been with the pharma company since 2010, when he joined from Schering-Plough (now part of Merck &Co) and subsequently held positions of increasing responsibility. ... In his new role Fiordaliso will report to Stephen Knowles, senior vice president

  • Intellia Therapeutics appoints Dr Moncef Slaoui and Dr Frank Verwiel Intellia Therapeutics appoints Dr Moncef Slaoui and Dr Frank Verwiel

    Intellia Therapeutics appoints Dr Moncef Slaoui and Dr Frank Verwiel. They will join the board of directors. ... Verwiel has also served at Merck &Co, where he was vice president and was general manager at Merck Sharpe Dohme’s operations in the

  • M3 appoints Paul Rice as chief operating officer M3 appoints Paul Rice as chief operating officer

    Prior to that Rice, who has over 25 years of industry experience, spent time as European commercial affairs director for Walgreens Boots and at Merck &Co as its EMEA executive director ... to drive M3’s growth in key markets and expand the services we

More from appointments
Approximately 4 fully matching, plus 31 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics